Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Crohn Disease: early-phase trial registry
34 of 72 indexed Crohn Disease trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #191 of 28,707 conditions by registered trial count.
72 US clinical trials · 34 currently recruiting · #191 of 28,707 conditions by registered trial count
Crohn Disease: 72 US clinical trials tracked, 34 recruiting.
Crohn Disease is the subject of 72 registered US clinical trials on ClinicalTrials.gov, 34 of them currently open to new participants. 13 are in Phase 3-4 (later-stage) and 20 in Phase 1-2 (earlier-stage). The most active sponsor is Massachusetts General Hospital, running 6 of these trials.
Enrollment posture brief
Registry condition crohn-disease
OPEN 34 | RECR 47% | LATE 13 | EARLY 20 | RANK #191 | SPON 6
Volume-matched condition peers
Nearest open-share peer: Psychosis (47% recruiting · 36 trials)
Crohn Disease lists 34 open slots (47% of 72 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Crohn Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Crohn Disease is recruiting above its size-band peers.
34 of 72 indexed trials (47.2%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Crohn Disease trials is spread across many organizations.
Massachusetts General Hospital accounts for 6 of 72 trials (8.3%). 51 distinct sponsors appear on at least one study for this condition label.
-
Typical Crohn Disease enrolment sits around 84 participants.
Median target enrolment is 84 among the 72 trials that report a genuine target (sentinel values excluded). 38 of those (52.8%) plan for fewer than 100 participants.
-
Crohn Disease research is mostly interventional.
58 interventional and 14 observational studies make up this index (80.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
72 total, page 1 of 2
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
Merck Sharp & Dohme
NCT06651281
Urine Metabolites in the Diagnosis of Disease
Luventix
NCT06710067
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
Janssen Research & Development
NCT07196722
A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis
Janssen Scientific Affairs
NCT04372108
Registry and Biorepository for IBD in Central Texas
University of Texas at Austin
NCT04617184
Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
Connecticut Children's Medical Center
NCT05781152
VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease
Alimentiv
NCT06257706
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
National Cancer Institute (NCI)
NCT03816345
Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
University of California, San Diego
NCT05230173
Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
University of California, San Diego
NCT02103361
Seattle Spatial Transcriptomic Research in Inflammatory Bowel Disease Evaluation (STRIDE)
Seattle Children's Hospital
NCT06315179
MeSenteric SpAring Versus High Ligation Ileocolic Resection for the Prevention of REcurrent Crohn's DiseaSe (SPARES)
The Cleveland Clinic
NCT04578392
Precise Infliximab Exposure and Pharmacodynamic Control
Children's Hospital Medical Center, Cincinnati
NCT05660746
Use of Psychologist-administered Cognitive Behavioral Therapy (CBT) or Self-administered CBT for the Treatment of Anxiety and/or Depression in Inflammatory Bowel Disease (IBD)
Yale University
NCT05377840
Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
M.D. Anderson Cancer Center
NCT04751396
Standardized Microbiota Transplant Therapy in Crohn's Disease
University of Minnesota
NCT06631586
Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy
Children's Hospital Medical Center, Cincinnati
NCT03847467
Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease
Massachusetts General Hospital
NCT04508088
RISE: A Remote Study of Insomnia Treatment in Crohn's Disease
Dartmouth-Hitchcock Medical Center
NCT05956158
Personalized Risk Estimation for Crohn's Disease (PRE-Crohn's): Implementation and Feasibility
Massachusetts General Hospital
NCT05332639
Impact of Prebiotics in Ulcerative Colitis
University of California, Los Angeles
NCT06495658
IBD-Sleep: A Pilot Study Looking at Changes in Sleep Timing and IBD Symptoms
University of Michigan
NCT06094608
Therapeutic Endpoint in Pediatric IBD Conditions
Children's National Research Institute
NCT06065228
Reverse-Engineering of Exclusive Enteral Nutrition (RE-EEN) in Crohn's Disease: A Multi-Center Trial
Seattle Children's Hospital
NCT06216899
Cranberry and Gut Health in Crohn's Disease
Ana Maldonado-Contreras
NCT07170462
High Dose Interval Vitamin D Supplementation in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy
Boston Children's Hospital
NCT04331639
Autologous Stem Cell Transplant for Crohn's Disease
Aaron Etra
NCT03219359
Low Dose IL-2 for the Treatment of Crohn's Disease
Boston Children's Hospital
NCT04263831
A Study for Imaging the Lower Gastrointestinal Tract Using a Retro-TCE Capsule
Massachusetts General Hospital
NCT07219537
Value of PET/MR Enterography in the Assessment of Crohn's Disease Using a Collagen-binding Radiotracer.
Massachusetts General Hospital
NCT06252493
Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients
University of Miami
NCT06774079
Effect of Statins on Crohn's Disease
Stanford University
NCT06538649
Stem Cell Transplantation in Crohn's Disease
Cedars-Sinai Medical Center
NCT04224558
Feasibility of a Wireless Thermal Capsule Endoscopy to Detect Gastrointestinal Thermal Variance
Massachusetts General Hospital
NCT07033208
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease
Janssen Research & Development
NCT05197049
Volatile Organic Compounds (VOCs) in Active Inflammatory Bowel Disease
The Cleveland Clinic
NCT04827368
A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease
Teva Branded Pharmaceutical Products R&D
NCT05668013
Biomarkers of Intestinal Fibrosis in Small Bowel Crohn's Disease
Children's Hospital Medical Center, Cincinnati
NCT04088773
Modulating Early Life Microbiome Through Dietary Intervention in Crohn's Disease
Icahn School of Medicine at Mount Sinai
NCT03850600
Combinatorial Single Cell Strategies for a Crohn's Disease Gut Cell Atlas
Vanderbilt University Medical Center
NCT04113733
A Long-term Extension Study of Ustekinumab in Pediatric Participants
Janssen Research & Development
NCT05092269
A Culturally Tailored Dietary Intervention to Treat Crohn's Disease
University of Massachusetts, Worcester
NCT05627128
Proactive Infliximab Optimization Using a Pharmacokinetic Dashboard Versus Standard of Care in Patients With Inflammatory Bowel Disease: The OPTIMIZE Trial
Beth Israel Deaconess Medical Center
NCT04835506
A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy
University of Maryland, Baltimore
NCT05316584
Safety and Efficacy of EcoActive on Intestinal Adherent Invasive E. Coli in Patients With Inactive Crohn's Disease
Intralytix
NCT03808103
Contrast Enhanced Ultrasound in Human Crohn's Disease-Lumason
Children's Hospital Medical Center, Cincinnati
NCT03492944
A Phase 2 Clinical Trial: Xanthohumol Metabolism and Signature (XMaS) in Crohn's Disease
National University of Natural Medicine
NCT04590508
Feasibility Study to Assess a Trans-nasal Intestinal Potential Difference Probe
Massachusetts General Hospital
NCT04565821
Addressing Disability Effectively With Psychosocial Telemedicine
University of Pennsylvania
NCT05635292
Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease
Janssen Research & Development
NCT02877134
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 11 |
| Phase 2 | 9 |
| Phase 3 | 5 |
| Phase 4 | 8 |
Top Sponsors
Named interventions
Most-linked intervention names on Crohn Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Crohn Disease trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Crohn Disease page
72 registered trials, 34 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 34 Crohn Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Massachusetts General Hospital sponsors the most Crohn Disease trials on record, review their full trial history before evaluating a specific study. See Massachusetts General Hospital's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Crohn Disease condition card totals 72 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.